Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia.

Leukemia & Lymphoma
Prajwal DhakalVijaya Raj Bhatt

Abstract

Polypharmacy, usually defined as taking ≥5 prescribed medications, increases chances of drug-drug interactions and toxicities, and may harm cancer patients who need multiple chemotherapeutic agents and supportive medications. We analyzed the effects of polypharmacy in overall survival (OS) in acute myeloid leukemia (AML). A total of 399 patients were divided into two groups: patients with polypharmacy (≥5 medications) versus without polypharmacy (<5 medications). Polypharmacy was associated with age ≥60 years, Karnofsky Performance Status of ≤80, hematopoietic cell transplant (HCT) comorbidity index of ≥5, and adverse cytogenetics. Patients with polypharmacy were less likely to receive intensity chemotherapy or HCT. One-year OS of patients with polypharmacy versus those without polypharmacy was 29 vs. 49% (p<.001). Polypharmacy conferred worse OS in patients <60 years (37 vs. 65% at 1 year, HR 1.95, 95% CI 1.21-3.15) but not in patients ≥60 years (26 vs. 27% at 1 year, HR 1.12, 95% CI 0.81-1.57). Thus, polypharmacy has negative impact on OS in AML, particularly among patients aged <60 years.

References

Sep 1, 1996·The American Journal of Emergency Medicine·R M GoldbergS Wong
Apr 29, 1998·JAMA : the Journal of the American Medical Association·J LazarouP N Corey
Jan 22, 2004·British Journal of Cancer·U WernekeD Fannon
Jul 3, 2004·BMJ : British Medical Journal·Munir PirmohamedAlasdair M Breckenridge
Apr 21, 2005·Health Affairs·Dana Gelb SafranWilliam H Rogers
Sep 1, 2005·Joint Commission Journal on Quality and Patient Safety·Chunliu ZhanDaniel Stryer
Mar 27, 2007·Journal of Clinical Pharmacy and Therapeutics·K C SokolM M Li
Aug 23, 2008·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Marie H HaniganPatrick J Medina
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Phyllis ButowMadeleine King
Apr 27, 2010·The Oncologist·Ronald J MaggioreArti Hurria
Jul 12, 2011·The Lancet Oncology·Judith Lees, Alexandre Chan
Dec 14, 2011·Journal of the American Geriatrics Society·Zachary A MarcumMary Jo V Pugh
Sep 6, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L BalducciM A Steinman
Mar 4, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Justin P TurnerJ Simon Bell
Aug 19, 2014·Research in Developmental Disabilities·Syed Imran HaiderEric Emerson
Mar 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ginah NightingaleAndrew Chapman
Apr 15, 2015·Journal of the American Medical Directors Association·Natali JokanovicJ Simon Bell
Oct 1, 2015·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Xiao-Cheng WuUNKNOWN AYA HOPE Study Collaborative Group
Oct 10, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Justin P TurnerJ Simon Bell
Aug 9, 2016·Journal of Geriatric Oncology·Manvi SharmaHolly M Holmes
Jan 20, 2017·Journal of Adolescent and Young Adult Oncology·L Aubree ShaySally W Vernon
Jun 3, 2017·Leukemia & Lymphoma·Vijaya Raj BhattLori J Maness
Oct 12, 2017·BMC Geriatrics·Nashwa MasnoonGillian E Caughey

❮ Previous
Next ❯

Citations

May 28, 2020·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Li-Ju ChenBen Schöttker
Sep 8, 2020·Hematological Oncology·Zuzana SustkovaJiri Mayer
Dec 5, 2020·Hematology·Anand P JillellaVamsi K Kota

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Canadian Medical Association Journal
JAMA : the Journal of the American Medical Association
Graziano Onder, Alessandra Marengoni
MMW Fortschritte der Medizin
Petra A Thürmann
Nursing Standard
Georgina Ingham
The Australian and New Zealand Journal of Psychiatry
S Lee
© 2021 Meta ULC. All rights reserved